Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CRNX NASDAQ:MLTX NASDAQ:SRRK NASDAQ:URGN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRNXCrinetics Pharmaceuticals$34.13+0.1%$31.12$24.10▼$62.53$3.22B0.28964,063 shs543,835 shsMLTXMoonLake Immunotherapeutics$51.10-4.1%$54.03$31.42▼$61.87$3.28B1.27505,711 shs1.17 million shsSRRKScholar Rock$31.95-1.2%$35.04$6.76▼$46.98$3.07B0.361.31 million shs1.31 million shsURGNUrogen Pharma$18.08+0.1%$18.37$3.42▼$21.71$836.52M1.11.52 million shs1.05 million shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRNXCrinetics Pharmaceuticals+0.98%-6.58%+11.00%+11.80%-36.78%MLTXMoonLake Immunotherapeutics-0.02%-6.56%-2.08%+22.44%+6.56%SRRKScholar Rock-3.95%+2.41%+2.96%-10.96%+299.26%URGNUrogen Pharma+0.06%-12.66%-8.32%+21.52%+36.89%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRNXCrinetics Pharmaceuticals$34.13+0.1%$31.12$24.10▼$62.53$3.22B0.28964,063 shs543,835 shsMLTXMoonLake Immunotherapeutics$51.10-4.1%$54.03$31.42▼$61.87$3.28B1.27505,711 shs1.17 million shsSRRKScholar Rock$31.95-1.2%$35.04$6.76▼$46.98$3.07B0.361.31 million shs1.31 million shsURGNUrogen Pharma$18.08+0.1%$18.37$3.42▼$21.71$836.52M1.11.52 million shs1.05 million shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRNXCrinetics Pharmaceuticals+0.98%-6.58%+11.00%+11.80%-36.78%MLTXMoonLake Immunotherapeutics-0.02%-6.56%-2.08%+22.44%+6.56%SRRKScholar Rock-3.95%+2.41%+2.96%-10.96%+299.26%URGNUrogen Pharma+0.06%-12.66%-8.32%+21.52%+36.89%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCRNXCrinetics Pharmaceuticals 2.75Moderate Buy$65.3391.45% UpsideMLTXMoonLake Immunotherapeutics 2.78Moderate Buy$74.4345.67% UpsideSRRKScholar Rock 3.23Buy$46.2044.60% UpsideURGNUrogen Pharma 3.00Buy$32.0076.96% UpsideCurrent Analyst Ratings BreakdownLatest URGN, MLTX, CRNX, and SRRK Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/17/2025SRRKScholar RockBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$45.009/15/2025SRRKScholar RockLeerink PartnrsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy9/15/2025SRRKScholar RockLeerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$51.008/21/2025SRRKScholar RockJefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$50.008/18/2025URGNUrogen PharmaPiper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$36.008/11/2025CRNXCrinetics PharmaceuticalsJMP SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetMarket Outperform$90.00 ➝ $86.008/11/2025URGNUrogen PharmaHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$50.00 ➝ $40.008/7/2025SRRKScholar RockBMO Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$57.00 ➝ $45.008/6/2025MLTXMoonLake ImmunotherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$74.00 ➝ $82.008/5/2025URGNUrogen PharmaD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$25.007/30/2025SRRKScholar RockRaymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetStrong-Buy$53.00(Data available from 9/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCRNXCrinetics Pharmaceuticals$1.04M3,090.37N/AN/A$14.29 per share2.39MLTXMoonLake ImmunotherapeuticsN/AN/AN/AN/A$7.09 per shareN/ASRRKScholar Rock$33.19M92.54N/AN/A$3.94 per share8.11URGNUrogen Pharma$90.40M9.25N/AN/A($0.21) per share-86.11Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCRNXCrinetics Pharmaceuticals-$298.41M-$4.11N/AN/AN/AN/A-32.28%-29.45%11/11/2025 (Estimated)MLTXMoonLake Immunotherapeutics-$118.94M-$2.78N/AN/AN/AN/A-40.98%-35.81%11/6/2025 (Estimated)SRRKScholar Rock-$246.29M-$2.91N/AN/AN/AN/A-127.11%-90.09%11/11/2025 (Estimated)URGNUrogen Pharma-$126.87M-$3.32N/AN/AN/A-164.44%-97,487.15%-59.38%11/5/2025 (Estimated)Latest URGN, MLTX, CRNX, and SRRK EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q2 2025CRNXCrinetics Pharmaceuticals-$1.13-$1.23-$0.10-$1.23$0.52 million$1.03 million8/7/2025Q2 2025URGNUrogen Pharma-$0.82-$1.05-$0.23-$1.05$23.06 million$24.22 million8/6/2025Q2 2025SRRKScholar Rock-$0.66-$0.98-$0.32-$0.98$0.11 millionN/A8/5/2025Q2 2025MLTXMoonLake Immunotherapeutics-$0.73-$0.87-$0.14-$0.87N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCRNXCrinetics PharmaceuticalsN/AN/AN/AN/AN/AMLTXMoonLake ImmunotherapeuticsN/AN/AN/AN/AN/ASRRKScholar RockN/AN/AN/AN/AN/AURGNUrogen PharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCRNXCrinetics PharmaceuticalsN/A17.8017.80MLTXMoonLake Immunotherapeutics0.2116.6516.65SRRKScholar Rock0.216.336.33URGNUrogen PharmaN/A4.143.99Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCRNXCrinetics Pharmaceuticals98.51%MLTXMoonLake Immunotherapeutics93.85%SRRKScholar Rock91.08%URGNUrogen Pharma91.29%Insider OwnershipCompanyInsider OwnershipCRNXCrinetics Pharmaceuticals6.00%MLTXMoonLake Immunotherapeutics12.05%SRRKScholar Rock13.30%URGNUrogen Pharma4.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCRNXCrinetics Pharmaceuticals21094.18 million88.53 millionOptionableMLTXMoonLake Immunotherapeutics264.23 million56.49 millionOptionableSRRKScholar Rock14096.13 million83.34 millionOptionableURGNUrogen Pharma20046.26 million44.09 millionOptionableURGN, MLTX, CRNX, and SRRK HeadlinesRecent News About These CompaniesUrogen Pharma $URGN Shares Purchased by UBS AM A Distinct Business Unit of UBS Asset Management Americas LLCSeptember 16 at 3:06 AM | marketbeat.comUrogen Pharma (NASDAQ:URGN) Raised to Hold at Wall Street ZenSeptember 15 at 2:07 AM | marketbeat.comUrogen Pharma (NASDAQ:URGN) Upgraded by Wall Street Zen to "Hold" RatingSeptember 14 at 3:55 AM | americanbankingnews.comTrexquant Investment LP Sells 157,097 Shares of Urogen Pharma $URGNSeptember 13, 2025 | marketbeat.comUrogen Pharma (NASDAQ:URGN) Stock Price Down 8% on Insider SellingSeptember 12, 2025 | marketbeat.comUrogen Pharma (NASDAQ:URGN) Insider Mark Schoenberg Sells 871 SharesSeptember 11, 2025 | marketbeat.comUrogen Pharma (NASDAQ:URGN) General Counsel Jason Drew Smith Sells 1,520 SharesSeptember 11, 2025 | marketbeat.comUrogen Pharma (NASDAQ:URGN) Reaches New 12-Month High - Should You Buy?September 11, 2025 | marketbeat.comUrogen Pharma (NASDAQ:URGN) Shares Down 8% Following Insider SellingSeptember 11, 2025 | americanbankingnews.comUrogen Pharma (NASDAQ:URGN) Shares Up 10.6% - What's Next?September 10, 2025 | marketbeat.comUrogen Pharma (NASDAQ:URGN) Insider Sells $16,644.81 in StockSeptember 10, 2025 | insidertrades.comUroGen Pharma announces inducement grants under Nasdaq listing ruleSeptember 9, 2025 | msn.comUroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)September 8, 2025 | globenewswire.comUrogen Pharma $URGN Holdings Boosted by Parkman Healthcare Partners LLCSeptember 8, 2025 | marketbeat.comUrogen Pharma $URGN Stock Position Decreased by Adage Capital Partners GP L.L.C.September 8, 2025 | marketbeat.comUrogen Pharma (NASDAQ:URGN) Receives Consensus Rating of "Buy" from AnalystsSeptember 8, 2025 | marketbeat.comUrogen Pharma (NASDAQ:URGN) Given Consensus Rating of "Buy" by AnalystsSeptember 7, 2025 | americanbankingnews.comVestal Point Capital LP Boosts Position in Urogen Pharma $URGNSeptember 4, 2025 | marketbeat.comRA Capital Management L.P. Acquires Shares of 3,206,271 Urogen Pharma $URGNSeptember 4, 2025 | marketbeat.comNuveen LLC Invests $1.03 Million in Urogen Pharma $URGNSeptember 3, 2025 | marketbeat.comPartners Capital Investment Group LLP Invests $170,000 in Urogen Pharma $URGNAugust 24, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeURGN, MLTX, CRNX, and SRRK Company DescriptionsCrinetics Pharmaceuticals NASDAQ:CRNX$34.13 +0.03 (+0.08%) Closing price 03:59 PM EasternExtended Trading$34.20 +0.07 (+0.22%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.MoonLake Immunotherapeutics NASDAQ:MLTX$51.10 -2.17 (-4.06%) Closing price 03:59 PM EasternExtended Trading$51.20 +0.11 (+0.21%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.Scholar Rock NASDAQ:SRRK$31.95 -0.39 (-1.21%) Closing price 03:59 PM EasternExtended Trading$31.96 +0.02 (+0.05%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.Urogen Pharma NASDAQ:URGN$18.08 +0.01 (+0.07%) Closing price 03:59 PM EasternExtended Trading$18.10 +0.02 (+0.09%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102 for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC). It is also developing UGN-301 for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; strategic research collaboration agreement with MD Anderson focusing on the sequential use of UGN-201 and UGN-301 for the treatment of NMIBC; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 in low-grade intermediate risk NMIBC and UGN-104 in low-grade upper tract urothelial carcinoma. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Broadcom Hits Record High After CEO Hock Tan AI Pay Package CrowdStrike Stock Set for Breakout as Agentic AI Demand Surges Why CoreWeave's NVIDIA Deal Creates a Deep Moat for AI Investors Resideo Technologies: Institutional Activity Signals 30% Upside This Stock Quietly Benefits From Oracle and NVIDIA’s AI Surge Rezolute Stock: FDA Fast Track Fuels 2025 Breakout Lululemon’s Sell-Off Looks Overdone: A Contrarian Case This Defense Stock Is Up 113% This Year—Is It Still a Buy? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
